



**e-therapeutics plc**  
("e-therapeutics" or the "Company")

### **Patent Filing Applications**

*Further advancement in the Company's RNAi Platform Development*

**Oxford, UK, 11 October 2021** - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a specialist in computational drug discovery with a focus on developing RNA interference ("RNAi") therapeutics, is pleased to announce new patent filings to protect the Company's proprietary RNAi platform technology for liver gene silencing.

The Company has recently filed five new patent applications relating to its innovative GalNAc-conjugated siRNA (short interfering RNA) construct designs, including around stabilising chemical modifications enabling specific hepatocyte (liver cell) targeting.

**Ali Mortazavi, Chief Executive Officer of e-therapeutics, commented:** *"Since our capital raise in May, we have made excellent progress in all areas of the Company. We expect to present data from our RNAi platform in our Interim Results announcement on Tuesday 26 October, when the in vivo characterisation studies will have been completed."*

#### **Enquiries:**

**e-therapeutics plc**  
Ali Mortazavi, CEO  
Karl Keegan, CFO  
Laura Roca-Alonso, CBO

Tel: +44 (0)1993 883 125  
[www.etherapeutics.co.uk](http://www.etherapeutics.co.uk)

**SP Angel Corporate Finance LLP**  
*Nominated Adviser and Broker*  
Matthew Johnson/Caroline Rowe (Corporate Finance)  
Vadim Alexandre/Rob Rees (Corporate Broking)

Tel: +44(0)20 3470 0470

#### **About e-therapeutics plc**

e-therapeutics plc is an Oxford, UK-based company integrating computational power and biology to accelerate the discovery of life-transforming medicines. The Company has developed and validated a powerful, disease and modality agnostic computational approach to drug discovery, leveraging its industry-leading expertise in network biology to fully capture and interrogate human disease complexity.

The Company's multi-disciplinary team builds computational models of biological functions to transform the search for new medicines, interventions, mechanisms and genetic support. Its biology-led *in silico* laboratory enables rapid hypothesis generation and phenotypic screening of millions of compounds leading to 100-1,000x higher hit rates in the wet lab and successful mode of action elucidation. Novel targets can also be identified, prioritised and assessed. Harnessing internal target gene discoveries, e-therapeutics is currently building an in-house pipeline of RNAi based medicines, using its proprietary GalNAc-siRNA technology.

e-therapeutics has deployed and validated its disease-agnostic computational drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top five pharmaceutical company.